Selected Drugs Clear All
MultiCheck Results
- 16
Interactions
Avoid/Use Alternative |
||
|
Lorbrena
(lorlatinib) + Low-Ogestrel
(norgestrel/ ethinyl estradiol) |
||
Avoid/Use Alternativelorlatinib + ethinyl estradiol (contraceptive) use additional non-hormonal or alternative contraception during and x28 days after lorlatinib tx; monitor BP: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN (hepatic metabolism induced, P-gp-mediated transport induced, UGT induced; additive effects) lorlatinib + norgestrel (contraceptive) use additional non-hormonal or alternative contraception during and x28 days after lorlatinib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced) |
||
|
Lorbrena
(lorlatinib) + Orsythia
(levonorgestrel/ ethinyl estradiol) |
||
Avoid/Use Alternativelorlatinib + ethinyl estradiol (contraceptive) use additional non-hormonal or alternative contraception during and x28 days after lorlatinib tx; monitor BP: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN (hepatic metabolism induced, P-gp-mediated transport induced, UGT induced; additive effects) lorlatinib + levonorgestrel (contraceptive) use additional non-hormonal or alternative contraception during and x28 days after lorlatinib tx: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metabolism induced) |
||
|
Lorbrena
(lorlatinib) + Syeda
(drospirenone/ ethinyl estradiol) |
||
Avoid/Use Alternativelorlatinib + drospirenone (contraceptive) use additional non-hormonal or alternative contraception during and x28 days after lorlatinib tx: combo may decr. drospirenone levels, contraceptive efficacy (hepatic metabolism induced) lorlatinib + ethinyl estradiol (contraceptive) use additional non-hormonal or alternative contraception during and x28 days after lorlatinib tx; monitor BP: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. risk of HTN (hepatic metabolism induced, P-gp-mediated transport induced, UGT induced; additive effects) |
||
|
Low-Ogestrel
(norgestrel/ ethinyl estradiol) + Orsythia
(levonorgestrel/ ethinyl estradiol) |
||
Avoid/Use Alternativeethinyl estradiol (contraceptive) + ethinyl estradiol (contraceptive) avoid combo: combo may incr. risk of HTN, thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy) norgestrel (contraceptive) + levonorgestrel (contraceptive) avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy) |
||
|
Low-Ogestrel
(norgestrel/ ethinyl estradiol) + Syeda
(drospirenone/ ethinyl estradiol) |
||
Avoid/Use Alternativeethinyl estradiol (contraceptive) + ethinyl estradiol (contraceptive) avoid combo: combo may incr. risk of HTN, thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy) norgestrel (contraceptive) + drospirenone (contraceptive) avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy) |
||
|
Orsythia
(levonorgestrel/ ethinyl estradiol) + Syeda
(drospirenone/ ethinyl estradiol) |
||
Avoid/Use Alternativeethinyl estradiol (contraceptive) + ethinyl estradiol (contraceptive) avoid combo: combo may incr. risk of HTN, thromboembolism, endometrial hyperplasia, other adverse effects (additive effects, duplicate therapy) levonorgestrel (contraceptive) + drospirenone (contraceptive) avoid combo: combo may incr. risk of thromboembolism, other adverse effects (additive effects, duplicate therapy) |
||
Monitor/Modify Tx |
||
|
Clenpiq
(sodium picosulfate/ magnesium oxide/ citric acid) + Truxima (rituximab-abbs)
(rituximab) |
||
Caution Advised |
||
|
Clenpiq
(sodium picosulfate/ magnesium oxide/ citric acid) + Lorbrena
(lorlatinib) |
||
Additional Considerations |
||
|
magnesium citrate
in Clenpiq
|
||
|
separate administration from other oral drugs by at least 1h; magnesium citrate may decr. absorption of concomitant oral drugs |
||
|
sodium picosulfate
in Clenpiq
|
||
|
separate administration from other oral drugs by at least 1h; sodium picosulfate may decr. absorption of concomitant oral drugs |
||